Severity of liver test abnormalities in coronavirus disease 2019 depends on comorbidities and predicts early in-hospital mortality
Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved..
BACKGROUND AND AIMS: Liver chemistry abnormalities (LCA) are common in patients with coronavirus disease 2019 (COVID-19), but their causes and clinical impact have not been adequately studied. We assessed the associations between LCA and clinical characteristics, inflammatory serum markers, in-hospital mortality.
METHODS: Ten thousand eight hundred fifty-six adult patients with COVID-19 hospitalized in 13 hospitals in New York (1 March to 27 April 2020) were analyzed retrospectively. Abnormalities of liver chemistries [aspartate aminotransferase (AST), alanine aminotransferase, alkaline phosphatase, or total bilirubin] were defined as absent, mild-moderate (at least one value up to four times elevated), or severe.
RESULTS: LCA were mild-moderate in 63.9% and severe in 7.6% at admission. Risk factors for severe LCA were male sex and chronic liver disease. Conversely, hypertension and diabetes mellitus were less likely associated with severe LCA. AST elevation correlated weakly to modestly with inflammatory markers. On adjusted analysis, in-hospital mortality was 1.56 times and 1.87 times increased in patients with mild-to-moderate and severe LCA, respectively. Diabetes, hypertension, male sex, and age greater than 60 years was associated with incremental risk of mortality with increase severity of LCA, especially in the first week of hospitalization. HTN was not associated with increased in-hospital mortality unless LCA was present.
CONCLUSION: Increasing severity of LCA on hospital admission predicts early in-hospital mortality in COVID-19 patients. Mortality associated with the known risk factors, hypertension, diabetes, male sex, and old age was accentuated in the presence of LCA. AST correlated modestly with inflammatory markers.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:33 |
|---|---|
| Enthalten in: |
European journal of gastroenterology & hepatology - 33(2021), 1S Suppl 1 vom: 01. Dez., Seite e320-e328 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Satapathy, Sanjaya K [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Completed 25.01.2022 Date Revised 09.03.2022 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1097/MEG.0000000000002055 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM321210263 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM321210263 | ||
| 003 | DE-627 | ||
| 005 | 20231225175326.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1097/MEG.0000000000002055 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1070.xml |
| 035 | |a (DE-627)NLM321210263 | ||
| 035 | |a (NLM)33560687 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Satapathy, Sanjaya K |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Severity of liver test abnormalities in coronavirus disease 2019 depends on comorbidities and predicts early in-hospital mortality |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 25.01.2022 | ||
| 500 | |a Date Revised 09.03.2022 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved. | ||
| 520 | |a BACKGROUND AND AIMS: Liver chemistry abnormalities (LCA) are common in patients with coronavirus disease 2019 (COVID-19), but their causes and clinical impact have not been adequately studied. We assessed the associations between LCA and clinical characteristics, inflammatory serum markers, in-hospital mortality | ||
| 520 | |a METHODS: Ten thousand eight hundred fifty-six adult patients with COVID-19 hospitalized in 13 hospitals in New York (1 March to 27 April 2020) were analyzed retrospectively. Abnormalities of liver chemistries [aspartate aminotransferase (AST), alanine aminotransferase, alkaline phosphatase, or total bilirubin] were defined as absent, mild-moderate (at least one value up to four times elevated), or severe | ||
| 520 | |a RESULTS: LCA were mild-moderate in 63.9% and severe in 7.6% at admission. Risk factors for severe LCA were male sex and chronic liver disease. Conversely, hypertension and diabetes mellitus were less likely associated with severe LCA. AST elevation correlated weakly to modestly with inflammatory markers. On adjusted analysis, in-hospital mortality was 1.56 times and 1.87 times increased in patients with mild-to-moderate and severe LCA, respectively. Diabetes, hypertension, male sex, and age greater than 60 years was associated with incremental risk of mortality with increase severity of LCA, especially in the first week of hospitalization. HTN was not associated with increased in-hospital mortality unless LCA was present | ||
| 520 | |a CONCLUSION: Increasing severity of LCA on hospital admission predicts early in-hospital mortality in COVID-19 patients. Mortality associated with the known risk factors, hypertension, diabetes, male sex, and old age was accentuated in the presence of LCA. AST correlated modestly with inflammatory markers | ||
| 650 | 4 | |a Journal Article | |
| 700 | 1 | |a Kuntzen, Christian |e verfasserin |4 aut | |
| 700 | 1 | |a Qiu, He |e verfasserin |4 aut | |
| 700 | 1 | |a Jiang, Yu |e verfasserin |4 aut | |
| 700 | 1 | |a Bodenheimer, Henry C |e verfasserin |4 aut | |
| 700 | 1 | |a Roth, Nitzan C |e verfasserin |4 aut | |
| 700 | 1 | |a Lee, Tai-Ping |e verfasserin |4 aut | |
| 700 | 1 | |a Hirsch, Jamie S |e verfasserin |4 aut | |
| 700 | 1 | |a Trindade, Arvind J |e verfasserin |4 aut | |
| 700 | 1 | |a Bernstein, David E |e verfasserin |4 aut | |
| 700 | 0 | |a Northwell Health COVID-19 Research Consortium |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t European journal of gastroenterology & hepatology |d 1996 |g 33(2021), 1S Suppl 1 vom: 01. Dez., Seite e320-e328 |w (DE-627)NLM074735322 |x 1473-5687 |7 nnns |
| 773 | 1 | 8 | |g volume:33 |g year:2021 |g number:1S Suppl 1 |g day:01 |g month:12 |g pages:e320-e328 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1097/MEG.0000000000002055 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 33 |j 2021 |e 1S Suppl 1 |b 01 |c 12 |h e320-e328 | ||